NTI

NEUROTECH FPO [NTI]
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains. The company has a collaboration with The University of Sydney. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0130 +0.0%

Updated 9 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when NTI triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track NTI — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is picking up steam
  • Drifting lower — down 3.7% over the last 5 days
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Low cash runway (2 quarters) - dilution risk
  • Low P/S ratio (4.8x)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (2.41%/day)
  • Altman Z-Score distress zone (1.52 < 1.81, low-confidence approx)
  • Penny stock risk ($0.014)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-138%)
  • Not enough chatter to gauge sentiment — defaulting to neutral

Expected next for NTI

2 Nov 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 26 Oct to 9 Nov
The last 7 moved NTI -2.8% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →

Recent Catalysts

NONE Initial Director's Interest Notice
NONE Notification of cessation of securities - NTI
NONE Board and Management Changes
Announcement tone +3pts

Recent ASX Announcements

2026-09-08 Initial Director's Interest Notice
2026-09-08 Notification of cessation of securities - NTI
2026-09-07 Board and Management Changes
2026-09-07 Final Director's Interest Notice
2026-08-26 Appendix 4G and Corporate Governance Statement

Key Metrics

$22.6M
Market Cap
3.1M
Avg Volume
0.7x
Vol Ratio
$0.01 — $0.03
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-366.7%
ROE
-138.1%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 62%
LLeader vs LaggardlaggardRS: -11
IInstitutional SponsorshipweakInst: 8%
MMarket DirectionneutralNeutral

Sector: Healthcare

110 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
NUZ +37.1%IPD +20.0%HIQ +16.7%AVE +15.0%CVB +11.1%
Compare:NTI vs NUZNTI vs IPDNTI vs HIQ
Share this analysis

Track NTI and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required